{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:37:56Z","timestamp":1786361876589,"version":"build-2736575974"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10787-025-02052-x","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:44:18Z","timestamp":1764204258000},"page":"319-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Kynurenine pathway in Parkinson\u2019s disease: pathophysiological roles and therapeutic interventions"],"prefix":"10.1007","volume":"34","author":[{"given":"Aganta","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal","family":"Bhui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-2830","authenticated-orcid":false,"given":"Sumel","family":"Ashique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-8121","authenticated-orcid":false,"given":"Biplab","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2052_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.105997","volume":"177","author":"IY Abdi","year":"2023","unstructured":"Abdi IY, Bartl M, Dakna M et al (2023) Cross-sectional proteomic expression in Parkinson\u2019s disease-related proteins in drug-na\u00efve patients vs healthy controls with longitudinal clinical follow-up. Neurobiol Dis 177:105997. https:\/\/doi.org\/10.1016\/j.nbd.2023.105997","journal-title":"Neurobiol Dis"},{"issue":"5","key":"2052_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1212\/wnl.0000000000000641","volume":"83","author":"CH Adler","year":"2014","unstructured":"Adler CH, Beach TG, Hentz JG et al (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406\u2013412. https:\/\/doi.org\/10.1212\/wnl.0000000000000641","journal-title":"Neurology"},{"issue":"4","key":"2052_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5603\/pjnns.a2023.0044","volume":"57","author":"P Alster","year":"2023","unstructured":"Alster P, Madetko-Alster N, Otto-\u015alusarczyk D et al (2023) Role of orexin in pathogenesis of neurodegenerative parkinsonisms. Neurol Neurochir Pol 57(4):335\u2013343. https:\/\/doi.org\/10.5603\/pjnns.a2023.0044","journal-title":"Neurol Neurochir Pol"},{"issue":"22","key":"2052_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212379","volume":"25","author":"R Arya","year":"2024","unstructured":"Arya R, Haque A, Shakya H et al (2024) Parkinson\u2019s disease: biomarkers for diagnosis and disease progression. Int J Mol Sci 25(22):12379. https:\/\/doi.org\/10.3390\/ijms252212379","journal-title":"Int J Mol Sci"},{"key":"2052_CR5","doi-asserted-by":"publisher","unstructured":"Ayd\u0131n EB, Ayd\u0131n M and Sezgint\u00fcrk MK (2023) Biosensors for saliva biomarkers. Advances in Clinical Chemistry. Elsevier, pp. 1\u201341. https:\/\/doi.org\/10.1016\/bs.acc.2022.11.001","DOI":"10.1016\/bs.acc.2022.11.001"},{"key":"2052_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1178646917691938","volume":"10","author":"AA Badawy","year":"2017","unstructured":"Badawy AA (2017) Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 10:1178646917691938. https:\/\/doi.org\/10.1177\/1178646917691938","journal-title":"Int J Tryptophan Res"},{"key":"2052_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2025.138220","volume":"854","author":"E Balog","year":"2025","unstructured":"Balog E, Jenei G, Berk\u00f3 AM et al (2025) Age-dependent changes in NMDA-induced excitotoxicity and neuromodulatory effects of kynurenic acid and its analogue in mouse brain slices. Neurosci Lett 854:138220. https:\/\/doi.org\/10.1016\/j.neulet.2025.138220","journal-title":"Neurosci Lett"},{"key":"2052_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.neurobiolaging.2016.06.001","volume":"45","author":"S Bandr\u00e9s-Ciga","year":"2016","unstructured":"Bandr\u00e9s-Ciga S, Price TR, Barrero FJ et al (2016) Genome-wide assessment of Parkinson\u2019s disease in a Southern Spanish population. Neurobiol Aging 45:213. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.06.001","journal-title":"Neurobiol Aging"},{"key":"2052_CR9","doi-asserted-by":"publisher","first-page":"1217090","DOI":"10.1016\/j.neurobiolaging.2016.06.001","volume":"16","author":"MR Battaglia","year":"2023","unstructured":"Battaglia MR, Di Fazio C, Battaglia S (2023) Activated Tryptophan-Kynurenine metabolic system in the human brain is associated with learned fear. Front Mol Neurosci 16:1217090. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.06.001","journal-title":"Front Mol Neurosci"},{"key":"2052_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.09.004","volume":"122","author":"R Baumgartner","year":"2019","unstructured":"Baumgartner R, Forteza MJ, Ketelhuth DFJ (2019) The interplay between cytokines and the kynurenine pathway in inflammation and atherosclerosis. Cytokine 122:154148. https:\/\/doi.org\/10.1016\/j.cyto.2017.09.004","journal-title":"Cytokine"},{"issue":"5","key":"2052_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal MF, Oakes D, Shoulson I et al (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71(5):543\u2013552. https:\/\/doi.org\/10.1001\/jamaneurol.2014.131","journal-title":"JAMA Neurol"},{"issue":"12","key":"2052_CR12","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1124\/dmd.112.046532","volume":"40","author":"MG Beconi","year":"2012","unstructured":"Beconi MG, Yates D, Lyons K et al (2012) Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab Dispos 40(12):2297\u20132306. https:\/\/doi.org\/10.1124\/dmd.112.046532","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"2052_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136737","volume":"22","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur I, Sehgal A et al (2021) The footprint of kynurenine pathway in neurodegeneration: Janus-faced role in Parkinson\u2019s disorder and therapeutic implications. Int J Mol Sci 22(13):6737. https:\/\/doi.org\/10.3390\/ijms22136737","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2052_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s1474-4422(23)00124-2","volume":"22","author":"D Berg","year":"2023","unstructured":"Berg D, Klein C (2023) \u03b1-synuclein seed amplification and its uses in Parkinson\u2019s disease. Lancet Neurol 22(5):369\u2013371. https:\/\/doi.org\/10.1016\/s1474-4422(23)00124-2","journal-title":"Lancet Neurol"},{"issue":"10","key":"2052_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14728222.2021.1999928","volume":"25","author":"FA Boros","year":"2021","unstructured":"Boros FA, Vecsei L (2021) Tryptophan 2, 3-dioxygenase, a novel therapeutic target for Parkinson\u2019s disease. Expert Opin Ther Targets 25(10):877\u2013888. https:\/\/doi.org\/10.1080\/14728222.2021.1999928","journal-title":"Expert Opin Ther Targets"},{"key":"2052_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105479","volume":"156","author":"M Bourque","year":"2024","unstructured":"Bourque M, Morissette M, Di Paolo T (2024) Neuroactive steroids and Parkinson\u2019s disease: review of human and animal studies. Neurosci Biobehav Rev 156:105479. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105479","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"2052_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.26992","volume":"32","author":"F Burt\u00e9","year":"2017","unstructured":"Burt\u00e9 F, Houghton D, Lowes H et al (2017) Metabolic profiling of Parkinson\u2019s disease and mild cognitive impairment. Mov Disord 32(6):927\u2013932. https:\/\/doi.org\/10.1002\/mds.26992","journal-title":"Mov Disord"},{"key":"2052_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00012","volume":"8","author":"BM Campbell","year":"2014","unstructured":"Campbell BM, Charych E, Lee AW et al (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 8:12. https:\/\/doi.org\/10.3389\/fnins.2014.00012","journal-title":"Front Neurosci"},{"issue":"24","key":"2052_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1212\/wnl.0000000000001681","volume":"84","author":"MC Campbell","year":"2015","unstructured":"Campbell MC, Koller JM, Snyder AZ et al (2015) CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology 84(24):2413\u20132421. https:\/\/doi.org\/10.1212\/wnl.0000000000001681","journal-title":"Neurology"},{"issue":"1","key":"2052_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02223-0","volume":"18","author":"I Castilla-Cort\u00e1zar","year":"2020","unstructured":"Castilla-Cort\u00e1zar I, Aguirre GA, Femat-Rold\u00e1n G et al (2020) Is insulin-like growth factor-1 involved in Parkinson\u2019s disease development? J Transl Med 18(1):70. https:\/\/doi.org\/10.1186\/s12967-020-02223-0","journal-title":"J Transl Med"},{"key":"2052_CR21","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/s1353-8020(13)70025-7","volume":"20","author":"LM Chahine","year":"2014","unstructured":"Chahine LM, Stern MB, Chen-Plotkin A (2014) Blood-based biomarkers for Parkinson\u2019s disease. Parkinsonism Relat Disord 20:S99\u2013S103. https:\/\/doi.org\/10.1016\/s1353-8020(13)70025-7","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2052_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12040955","volume":"12","author":"S Chakrabarti","year":"2023","unstructured":"Chakrabarti S, Bisaglia M (2023) Oxidative stress and neuroinflammation in Parkinson\u2019s disease: the role of dopamine oxidation products. Antioxidants 12(4):955. https:\/\/doi.org\/10.3390\/antiox12040955","journal-title":"Antioxidants"},{"issue":"3","key":"2052_CR23","doi-asserted-by":"publisher","DOI":"10.26599\/FSHW.2024.9250066","volume":"14","author":"B Chang","year":"2025","unstructured":"Chang B, Jiang Y, Feng C, Li B, Mei J, Niu C (2025) Effect of purine diet on prognosis of deep brain stimulation for Parkinson\u2019s disease. Food Sci Hum Wellness 14(3):9250066. https:\/\/doi.org\/10.26599\/FSHW.2024.9250066","journal-title":"Food Sci Hum Wellness"},{"issue":"8","key":"2052_CR24","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"KH Chang","year":"2018","unstructured":"Chang KH, Cheng ML, Tang HY et al (2018) Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson\u2019s disease. Mol Neurobiol 55(8):6319\u20136328. https:\/\/doi.org\/10.1007\/s12035-017-0845-3","journal-title":"Mol Neurobiol"},{"key":"2052_CR25","doi-asserted-by":"publisher","unstructured":"Chen W-R, Chen J-C, Chang S-Y, et al. (2022) Phosphorylated \u03b1-synuclein in diluted human serum as a Chen, Y., Yin, P., Chen, Q., Zhang, Y., Tang, Y., Jin, W., & Yu, L. (2025). Neurodegenerative diseases and immune system: From pathogenic mechanism to therapy. Neural regeneration research, https:\/\/doi.org\/10.4103\/NRR.NRR-D-25-00274. Advance online publication.  https:\/\/doi.org\/10.4103\/NRR.NRR-D-25-00274biomarkerfor Parkinson\u2019s disease. Biomed J 45(6): 914\u2013922. https:\/\/doi.org\/10.1016\/j.bj.2021.12.010","DOI":"10.4103\/NRR.NRR-D-25-00274"},{"issue":"7","key":"2052_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu15071737","volume":"15","author":"C Chu","year":"2023","unstructured":"Chu C, Yu L, Li Y et al (2023) Lactobacillus plantarum CCFM405 against rotenone-induced Parkinson\u2019s disease mice via regulating gut microbiota and branched-chain amino acids biosynthesis. Nutrients 15(7):1737. https:\/\/doi.org\/10.3390\/nu15071737","journal-title":"Nutrients"},{"issue":"5","key":"2052_CR27","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2022.2022-7-100","volume":"39","author":"E \u00c7\u0131nar","year":"2022","unstructured":"\u00c7\u0131nar E, Tel BC, \u015eahin G (2022) Neuroinflammation in Parkinson\u2019s disease and its treatment opportunities. Balkan Med J 39(5):318. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2022.2022-7-100","journal-title":"Balkan Med J"},{"issue":"47","key":"2052_CR28","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1021\/bi8010434","volume":"47","author":"KR Crozier-Reabe","year":"2008","unstructured":"Crozier-Reabe KR, Phillips RS, Moran GR (2008) Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide. Biochemistry 47(47):12420\u201312433. https:\/\/doi.org\/10.1021\/bi8010434","journal-title":"Biochemistry"},{"key":"2052_CR29","doi-asserted-by":"publisher","first-page":"1221438","DOI":"10.3389\/fnut.2023.1221438","volume":"10","author":"D Das","year":"2023","unstructured":"Das D, Shruthi NR, Banerjee A et al (2023) Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies. Front Nutr 10:1221438. https:\/\/doi.org\/10.3389\/fnut.2023.1221438","journal-title":"Front Nutr"},{"issue":"Suppl 1","key":"2052_CR30","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","volume":"22 Suppl 1","author":"M Delenclos","year":"2016","unstructured":"Delenclos M, Jones DR, McLean PJ et al (2016) Biomarkers in Parkinson\u2019s disease: advances and strategies. Parkinsonism Relat Disord 22 Suppl 1(Suppl 1):S106-110. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.048","journal-title":"Parkinsonism Relat Disord"},{"key":"2052_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neulet.2013.08.028","volume":"553","author":"I Demeter","year":"2013","unstructured":"Demeter I, Nagy K, Farkas T et al (2013) Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study. Neurosci Lett 553:138\u2013141. https:\/\/doi.org\/10.1016\/j.neulet.2013.08.028","journal-title":"Neurosci Lett"},{"issue":"12","key":"2052_CR32","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1021\/acschemneuro.7b00229","volume":"8","author":"GS Deora","year":"2017","unstructured":"Deora GS, Kantham S, Chan S et al (2017) Multifunctional analogs of kynurenic acid for the treatment of Alzheimer\u2019s disease: synthesis, pharmacology, and molecular modeling studies. ACS Chem Neurosci 8(12):2667\u20132675. https:\/\/doi.org\/10.1021\/acschemneuro.7b00229","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"2052_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/jpd-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3(4):461\u2013491. https:\/\/doi.org\/10.3233\/jpd-130230","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"2052_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10571-021-01066-7","volume":"42","author":"N Dogra","year":"2022","unstructured":"Dogra N, Mani RJ, Katare DP (2022) The gut-brain axis: two ways signaling in Parkinson\u2019s disease. Cell Mol Neurobiol 42(2):315\u2013332. https:\/\/doi.org\/10.1007\/s10571-021-01066-7","journal-title":"Cell Mol Neurobiol"},{"key":"2052_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2021.105112","volume":"239","author":"M-X Dong","year":"2021","unstructured":"Dong M-X, Wei Y-D, Hu L (2021) The disturbance of lipid metabolism is correlated with neuropsychiatric symptoms in patients with Parkinson\u2019s disease. Chem Phys Lipids 239:105112. https:\/\/doi.org\/10.1016\/j.chemphyslip.2021.105112","journal-title":"Chem Phys Lipids"},{"key":"2052_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997240","volume":"13","author":"M Fathi","year":"2022","unstructured":"Fathi M, Vakili K, Yaghoobpoor S et al (2022) Dynamic changes in metabolites of the kynurenine pathway in Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease: a systematic review and meta-analysis. Front Immunol 13:997240. https:\/\/doi.org\/10.3389\/fimmu.2022.997240","journal-title":"Front Immunol"},{"issue":"5","key":"2052_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1124\/mol.111.074765","volume":"81","author":"F Fazio","year":"2012","unstructured":"Fazio F, Lionetto L, Molinaro G et al (2012) Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol 81(5):643\u2013656. https:\/\/doi.org\/10.1124\/mol.111.074765","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2052_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02446-6","volume":"19","author":"J Fu","year":"2022","unstructured":"Fu J, Huang Y, Bao T et al (2022) The role of Th17 cells\/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A. J Neuroinflamm 19(1):98. https:\/\/doi.org\/10.1186\/s12974-022-02446-6","journal-title":"J Neuroinflamm"},{"issue":"13","key":"2052_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137144","volume":"25","author":"M Fujikawa","year":"2024","unstructured":"Fujikawa M, Ueda M, Maruyama K (2024) Role of kynurenine and its derivatives in the neuroimmune system. Int J Mol Sci 25(13):7144. https:\/\/doi.org\/10.3390\/ijms25137144","journal-title":"Int J Mol Sci"},{"key":"2052_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.neuropharm.2013.08.002","volume":"76","author":"K Fukuyama","year":"2014","unstructured":"Fukuyama K, Tanahashi S, Hoshikawa M et al (2014) Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology 76:137\u2013145. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.002","journal-title":"Neuropharmacology"},{"issue":"51","key":"2052_CR41","doi-asserted-by":"publisher","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","volume":"288","author":"F Giorgini","year":"2013","unstructured":"Giorgini F, Huang SY, Sathyasaikumar KV et al (2013) Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 288(51):36554\u201336566. https:\/\/doi.org\/10.1074\/jbc.M113.503813","journal-title":"J Biol Chem"},{"issue":"1","key":"2052_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43096-9","volume":"13","author":"D Gu\u00e9vremont","year":"2023","unstructured":"Gu\u00e9vremont D, Roy J, Cutfield NJ et al (2023) Micrornas in Parkinson\u2019s disease: a systematic review and diagnostic accuracy meta-analysis. Sci Rep 13(1):16272. https:\/\/doi.org\/10.1038\/s41598-023-43096-9","journal-title":"Sci Rep"},{"issue":"3","key":"2052_CR43","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1086\/318788","volume":"68","author":"HM Gurling","year":"2001","unstructured":"Gurling HM, Kalsi G, Brynjolfson J et al (2001) Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32. 2, 5q33. 2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23. 3-24 and 20q12. 1-11.23. Am J Hum Genet 68(3):661\u2013673. https:\/\/doi.org\/10.1086\/318788","journal-title":"Am J Hum Genet"},{"issue":"1-3","key":"2052_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2008.02.052","volume":"586","author":"M Hamann","year":"2008","unstructured":"Hamann M, Sander SE, Richter A (2008) Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dtsz mutant. Eur J Pharmacol 586(1\u20133):156\u2013159. https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.052","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2052_CR45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.14104","volume":"142","author":"JF Havelund","year":"2017","unstructured":"Havelund JF, Andersen AD, Binzer M et al (2017) Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem 142(5):756\u2013766. https:\/\/doi.org\/10.1111\/jnc.14104","journal-title":"J Neurochem"},{"issue":"2-3","key":"2052_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000511083","volume":"20","author":"S He","year":"2020","unstructured":"He S, Zhong S, Liu G et al (2020) Alpha-synuclein: the interplay of pathology, neuroinflammation, and environmental factors in Parkinson\u2019s disease. Neurodegener Dis 20(2\u20133):55\u201364. https:\/\/doi.org\/10.1159\/000511083","journal-title":"Neurodegener Dis"},{"issue":"11","key":"2052_CR47","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/mds.28202","volume":"35","author":"PL Heilman","year":"2020","unstructured":"Heilman PL, Wang EW, Lewis MM et al (2020) Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson\u2019s disease. Mov Disord 35(11):2028\u20132037. https:\/\/doi.org\/10.1002\/mds.28202","journal-title":"Mov Disord"},{"key":"2052_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/11786469231213521","volume":"16","author":"B Heng","year":"2023","unstructured":"Heng B, Pires AS, Chow S et al (2023) Stability studies of kynurenine pathway metabolites in blood components define optimal blood processing conditions. Int J Tryptophan Res 16:11786469231213521. https:\/\/doi.org\/10.1177\/11786469231213521","journal-title":"Int J Tryptophan Res"},{"issue":"8","key":"2052_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070951","volume":"8","author":"D Hernandez-Baltazar","year":"2013","unstructured":"Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D (2013) Activation of GSK-3\u03b2 and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS ONE 8(8):e70951. https:\/\/doi.org\/10.1371\/journal.pone.0070951","journal-title":"PLoS ONE"},{"issue":"7","key":"2052_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/biom12070998","volume":"12","author":"K Hestad","year":"2022","unstructured":"Hestad K, Alexander J, Rootwelt H et al (2022) The role of tryptophan dysmetabolism and quinolinic acid in depressive and neurodegenerative diseases. Biomolecules 12(7):998. https:\/\/doi.org\/10.3390\/biom12070998","journal-title":"Biomolecules"},{"issue":"6","key":"2052_CR51","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"2052_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.chaos.2025.116267","volume":"195","author":"B Hu","year":"2025","unstructured":"Hu B, Wang X, Lu S, Ying X (2025) A study of bidirectional control of Parkinson\u2019s beta oscillations by basal ganglia. Chaos Solitons Fractals 195:116267. https:\/\/doi.org\/10.1016\/j.chaos.2025.116267","journal-title":"Chaos Solitons Fractals"},{"key":"2052_CR53","unstructured":"Ibrahim N, Kusmirek J, Struck AF, et al. (2016) The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am J Nucl Med Mol Imaging 6(1): 102PMID: 27069770 PMCID: PMC4749509"},{"issue":"23","key":"2052_CR54","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2174\/0929867324666170502123114","volume":"24","author":"KR Jacobs","year":"2017","unstructured":"Jacobs KR, Castellano-Gonzalez G, Guillemin GJ et al (2017) Major developments in the design of inhibitors along the kynurenine pathway. Curr Med Chem 24(23):2471\u20132495. https:\/\/doi.org\/10.2174\/0929867324666170502123114","journal-title":"Curr Med Chem"},{"issue":"3","key":"2052_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.23750\/abm.v88i3.6063","volume":"88","author":"AJ Jagadeesan","year":"2017","unstructured":"Jagadeesan AJ, Murugesan R, Vimala Devi S, Meera M, Madhumala G, Vishwanathan Padmaja M, Ramesh A, Banerjee A, Sushmitha S, Khokhlov AN, Marotta F, Pathak S (2017) Current trends in etiology, prognosis and therapeutic aspects of Parkinson\u2019s disease: a review. Acta Biomed 88(3):249\u2013262. https:\/\/doi.org\/10.23750\/abm.v88i3.6063","journal-title":"Acta Biomed"},{"issue":"1","key":"2052_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00949-6","volume":"11","author":"LC Jellen","year":"2025","unstructured":"Jellen LC, Escobar Galvis ML, Sha Q et al (2025) Sex differences in peripheral and central dysregulation of the kynurenine pathway in Parkinson\u2019s disease. NPJ Parkinsons Dis 11(1):116. https:\/\/doi.org\/10.1038\/s41531-025-00949-6","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"2052_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048783","volume":"7","author":"S Jesse","year":"2012","unstructured":"Jesse S, Lehnert S, Jahn O et al (2012) Differential sialylation of serpin A1 in the early diagnosis of Parkinson\u2019s disease dementia. PLoS ONE 7(11):e48783. https:\/\/doi.org\/10.1371\/journal.pone.0048783","journal-title":"PLoS ONE"},{"key":"2052_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/1178646920938688","volume":"13","author":"N Joisten","year":"2020","unstructured":"Joisten N, Walzik D, Metcalfe AJ et al (2020) Physical exercise as kynurenine pathway modulator in chronic diseases: implications for immune and energy homeostasis. Int J Tryptophan Res 13:1178646920938688. https:\/\/doi.org\/10.1177\/1178646920938688","journal-title":"Int J Tryptophan Res"},{"issue":"18","key":"2052_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814251","volume":"24","author":"\u00c1 Juh\u00e1sz","year":"2023","unstructured":"Juh\u00e1sz \u00c1, Ungor D, Varga N et al (2023) Lipid-based nanocarriers for delivery of neuroprotective kynurenic acid: preparation, characterization, and BBB transport. Int J Mol Sci 24(18):14251. https:\/\/doi.org\/10.3390\/ijms241814251","journal-title":"Int J Mol Sci"},{"key":"2052_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1524651","volume":"14","author":"I Kang","year":"2025","unstructured":"Kang I, Theodoropoulos G, Wangpaichitr M (2025) Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells. Front Oncol 14:1524651. https:\/\/doi.org\/10.3389\/fonc.2024.1524651","journal-title":"Front Oncol"},{"issue":"3","key":"2052_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031842","volume":"24","author":"EA Katunina","year":"2023","unstructured":"Katunina EA, Blokhin V, Nodel MR et al (2023) Searching for biomarkers in the blood of patients at risk of developing Parkinson\u2019s disease at the prodromal stage. Int J Mol Sci 24(3):1842. https:\/\/doi.org\/10.3390\/ijms24031842","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2052_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-024-01496-z","volume":"44","author":"R Kearns","year":"2024","unstructured":"Kearns R (2024) Gut\u2013brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders. Cell Mol Neurobiol 44(1):64. https:\/\/doi.org\/10.1007\/s10571-024-01496-z","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"2052_CR63","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.clnu.2023.04.001","volume":"42","author":"C-S Kim","year":"2023","unstructured":"Kim C-S, Jung S, Hwang G-S et al (2023) Gut microbiota indole-3-propionic acid mediates neuroprotective effect of probiotic consumption in healthy elderly: a randomized, double-blind, placebo-controlled, multicenter trial and in vitro study. Clin Nutr 42(6):1025\u20131033. https:\/\/doi.org\/10.1016\/j.clnu.2023.04.001","journal-title":"Clin Nutr"},{"issue":"4","key":"2052_CR64","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.chembiol.2018.01.008","volume":"25","author":"HT Kim","year":"2018","unstructured":"Kim HT, Na BK, Chung J et al (2018a) Structural basis for inhibitor-induced hydrogen peroxide production by kynurenine 3-monooxygenase. Cell Chem Biol 25(4):426\u2013438. https:\/\/doi.org\/10.1016\/j.chembiol.2018.01.008","journal-title":"Cell Chem Biol"},{"issue":"3","key":"2052_CR65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12275-018-8032-4","volume":"56","author":"N Kim","year":"2018","unstructured":"Kim N, Yun M, Oh YJ et al (2018b) Mind-altering with the gut: modulation of the gut-brain axis with probiotics. J Microbiol 56(3):172\u2013182. https:\/\/doi.org\/10.1007\/s12275-018-8032-4","journal-title":"J Microbiol"},{"issue":"10","key":"2052_CR66","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nri3312","volume":"12","author":"TR Klaenhammer","year":"2012","unstructured":"Klaenhammer TR, Kleerebezem M, Kopp MV et al (2012) The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol 12(10):728\u2013734. https:\/\/doi.org\/10.1038\/nri3312","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2052_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00239-x","volume":"7","author":"S Klatt","year":"2021","unstructured":"Klatt S, Doecke JD, Roberts A et al (2021) A six-metabolite panel as potential blood-based biomarkers for Parkinson\u2019s disease. NPJ Parkinsons Dis 7(1):94. https:\/\/doi.org\/10.1038\/s41531-021-00239-x","journal-title":"NPJ Parkinsons Dis"},{"issue":"5","key":"2052_CR68","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/wnl.0000000000001807","volume":"85","author":"S Koga","year":"2015","unstructured":"Koga S, Aoki N, Uitti RJ et al (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85(5):404\u2013412. https:\/\/doi.org\/10.1212\/wnl.0000000000001807","journal-title":"Neurology"},{"issue":"6","key":"2052_CR69","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2021.0527","volume":"12","author":"L Leggio","year":"2021","unstructured":"Leggio L, Patern\u00f2 G, Vivarelli S et al (2021) Extracellular vesicles as novel diagnostic and prognostic biomarkers for Parkinson\u2019s disease. Aging Dis 12(6):1494. https:\/\/doi.org\/10.14336\/ad.2021.0527","journal-title":"Aging Dis"},{"issue":"1","key":"2052_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89168-6","volume":"11","author":"G Leodori","year":"2021","unstructured":"Leodori G, De Bartolo MI, Belvisi D et al (2021) Salivary caffeine in Parkinson\u2019s disease. Sci Rep 11(1):9823. https:\/\/doi.org\/10.1038\/s41598-021-89168-6","journal-title":"Sci Rep"},{"key":"2052_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256769","volume":"13","author":"RA Leon-Letelier","year":"2023","unstructured":"Leon-Letelier RA, Dou R, Vykoukal J et al (2023) The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer. Front Oncol 13:1256769. https:\/\/doi.org\/10.3389\/fonc.2023.1256769","journal-title":"Front Oncol"},{"key":"2052_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.574652","volume":"14","author":"C Li","year":"2020","unstructured":"Li C, Xue L, Liu Y et al (2020a) Zonisamide for the treatment of Parkinson disease: a current update. Front Neurosci 14:574652. https:\/\/doi.org\/10.3389\/fnins.2020.574652","journal-title":"Front Neurosci"},{"issue":"10","key":"2052_CR73","first-page":"7527","volume":"13","author":"SW Li","year":"2020","unstructured":"Li SW, Kuang ZD, Kuang WP (2020b) Protective effect of gastrodin on dopaminergic neurons by miR-24 targeting of the DJ-1\/Nrf2 pathway in Parkinson\u2019s disease. Int J Clin Exp Med 13(10):7527\u20137535","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"2052_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/efd2.156","volume":"5","author":"T Li","year":"2024","unstructured":"Li T, Zhang C, Wang Q et al (2024) Exploring the therapeutic potential of Bifidobacterium longum subsp. longum CCFM1029 in Parkinson\u2019s disease: insights from behavioral, neurophysiological, gut microbiota, and microbial metabolites analysis. eFood 5(5):e156. https:\/\/doi.org\/10.1002\/efd2.156","journal-title":"eFood"},{"issue":"4","key":"2052_CR75","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/schbul\/sbae063","volume":"50","author":"J Liang","year":"2024","unstructured":"Liang J, Chen L, Li Y, Chen Y, Yuan L, Qiu Y, Cheng Y (2024) Unraveling the prefrontal cortex-basolateral amygdala pathway\u2019s role on schizophrenia\u2019s cognitive impairments: a multimodal study in patients and mouse models. Schizophr Bull 50(4):913\u2013923. https:\/\/doi.org\/10.1093\/schbul\/sbae063","journal-title":"Schizophr Bull"},{"issue":"5","key":"2052_CR76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/acn3.299","volume":"3","author":"NS Lim","year":"2016","unstructured":"Lim NS, Swanson CR, Cherng HR et al (2016) Plasma EGF and cognitive decline in Parkinson\u2019s disease and Alzheimer\u2019s disease. Ann Clin Transl Neurol 3(5):346\u2013355. https:\/\/doi.org\/10.1002\/acn3.299","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2052_CR77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.62641\/aep.v52i5.1748","volume":"52","author":"H Liu","year":"2024","unstructured":"Liu H, Zhu K, Yang C (2024) The intersection between tryptophan-kynurenine pathway metabolites and immune inflammation, hormones, and gut microbiota in perinatal depression. Actas Esp Psiquiatr 52(5):733\u2013740. https:\/\/doi.org\/10.62641\/aep.v52i5.1748","journal-title":"Actas Esp Psiquiatr"},{"key":"2052_CR78","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","volume":"112","author":"MD Lovelace","year":"2017","unstructured":"Lovelace MD, Varney B, Sundaram G et al (2017) Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology 112:373\u2013388. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.03.024","journal-title":"Neuropharmacology"},{"issue":"1","key":"2052_CR79","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/pr500807t","volume":"14","author":"H Luan","year":"2015","unstructured":"Luan H, Liu L-F, Meng N et al (2015) LC\u2013MS-based urinary metabolite signatures in idiopathic Parkinson\u2019s disease. J Proteome Res 14(1):467\u2013478. https:\/\/doi.org\/10.1021\/pr500807t","journal-title":"J Proteome Res"},{"issue":"1","key":"2052_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00732-z","volume":"10","author":"X Luo","year":"2024","unstructured":"Luo X, Liu Y, Balck A et al (2024) Identification of metabolites reproducibly associated with Parkinson\u2019s Disease via meta-analysis and computational modelling. NPJ Parkinsons Dis 10(1):126. https:\/\/doi.org\/10.1038\/s41531-024-00732-z","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"2052_CR81","first-page":"1813","volume":"15","author":"ZL Ma","year":"2024","unstructured":"Ma ZL, Wang ZL, Zhang FY et al (2024) Biomarkers of Parkinson\u2019s disease: from basic research to clinical practice. Aging Dis 15(4):1813\u20131830","journal-title":"Aging Dis"},{"key":"2052_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113257","volume":"152","author":"P Majerova","year":"2022","unstructured":"Majerova P, Olesova D, Golisova G et al (2022) Analog of kynurenic acid decreases tau pathology by modulating astrogliosis in rat model for tauopathy. Biomed Pharmacother 152:113257. https:\/\/doi.org\/10.1016\/j.biopha.2022.113257","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2052_CR83","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/mds.28192","volume":"35","author":"I Markaki","year":"2020","unstructured":"Markaki I, Bergstr\u00f6m S, Tsitsi P et al (2020) Cerebrospinal fluid levels of Kininogen\u20101 indicate early cognitive impairment in Parkinson\u2019s Disease. Mov Disord 35(11):2101\u20132106. https:\/\/doi.org\/10.1002\/mds.28192","journal-title":"Mov Disord"},{"issue":"12","key":"2052_CR84","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00109-013-1075-4","volume":"91","author":"JF Mart\u00ed-Mass\u00f3","year":"2013","unstructured":"Mart\u00ed-Mass\u00f3 JF, Bergareche A, Makarov V et al (2013) The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. J Mol Med 91(12):1399\u20131406. https:\/\/doi.org\/10.1007\/s00109-013-1075-4","journal-title":"J Mol Med"},{"issue":"2","key":"2052_CR85","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1570159X20666220922153221","volume":"21","author":"LB Martins","year":"2023","unstructured":"Martins LB, Silveira AL, Teixeira AL (2023) The involvement of kynurenine pathway in neurodegenerative diseases. Curr Neuropharmacol 21(2):260\u2013272. https:\/\/doi.org\/10.2174\/1570159X20666220922153221","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"2052_CR86","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.410240415","volume":"24","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Akiyama H et al (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24(4):574\u2013576. https:\/\/doi.org\/10.1002\/ana.410240415","journal-title":"Ann Neurol"},{"issue":"2","key":"2052_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/2096595820902566","volume":"5","author":"L Meng","year":"2019","unstructured":"Meng L, Yuan X, Cao X et al (2019) The gut-brain axis in the pathogenesis of Parkinson\u2019s disease. Brain Sci Adv 5(2):73\u201381. https:\/\/doi.org\/10.1177\/2096595820902566","journal-title":"Brain Sci Adv"},{"key":"2052_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314997","author":"D Minchev","year":"2022","unstructured":"Minchev D, Kazakova M, Sarafian V (2022) Neuroinflammation and autophagy in Parkinson\u2019s disease-novel perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314997","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2052_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122623","volume":"9","author":"I Miyazaki","year":"2020","unstructured":"Miyazaki I, Asanuma M (2020) Neuron-astrocyte interactions in Parkinson\u2019s disease. Cells 9(12):2623. https:\/\/doi.org\/10.3390\/cells9122623","journal-title":"Cells"},{"issue":"1","key":"2052_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010061","volume":"13","author":"K Moln\u00e1r","year":"2021","unstructured":"Moln\u00e1r K, L\u0151rinczi B, Fazakas C et al (2021) Szr-104, a novel kynurenic acid analogue with high permeability through the blood\u2013brain barrier. Pharmaceutics 13(1):61. https:\/\/doi.org\/10.3390\/pharmaceutics13010061","journal-title":"Pharmaceutics"},{"issue":"15","key":"2052_CR91","doi-asserted-by":"publisher","first-page":"e2095","DOI":"10.1212\/wnl.0000000000010523","volume":"95","author":"S Molsberry","year":"2020","unstructured":"Molsberry S, Bjornevik K, Hughes KC et al (2020) Diet pattern and prodromal features of Parkinson disease. Neurology 95(15):e2095\u2013e2108. https:\/\/doi.org\/10.1212\/wnl.0000000000010523","journal-title":"Neurology"},{"key":"2052_CR92","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2017.07.008","volume":"810","author":"K O'Farrell","year":"2017","unstructured":"O\u2019Farrell K, Fagan E, Connor TJ et al (2017) Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. Eur J Pharmacol 810:163\u2013173. https:\/\/doi.org\/10.1016\/j.ejphar.2017.07.008","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2052_CR93","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/ana.24553","volume":"79","author":"S Olgiati","year":"2016","unstructured":"Olgiati S, Quadri M, Fang M et al (2016) D NAJC 6 Mutations associated W ith Early\u2010Onset P arkinson\u2019s Disease. Ann Neurol 79(2):244\u2013256. https:\/\/doi.org\/10.1002\/ana.24553","journal-title":"Ann Neurol"},{"key":"2052_CR94","doi-asserted-by":"publisher","DOI":"10.1177\/11786469241245323","volume":"17","author":"F Orhan","year":"2024","unstructured":"Orhan F, Schwieler L, Engberg G et al (2024) Kynurenine metabolites in CSF and plasma in healthy males. Int J Tryptophan Res 17:11786469241245323. https:\/\/doi.org\/10.1177\/11786469241245323","journal-title":"Int J Tryptophan Res"},{"issue":"1","key":"2052_CR95","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cns.13768","volume":"28","author":"A Ostapiuk","year":"2022","unstructured":"Ostapiuk A, Urbanska EM (2022) Kynurenic acid in neurodegenerative disorders\u2014unique neuroprotection or double\u2010edged sword? CNS Neurosci Ther 28(1):19\u201335. https:\/\/doi.org\/10.1111\/cns.13768","journal-title":"CNS Neurosci Ther"},{"key":"2052_CR96","doi-asserted-by":"crossref","unstructured":"Oxenkrug G, van der Hart M, Roeser J, et al. (2017) Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson\u2019s and Alzheimer\u2019s Diseases. Endocrinol Diabetes Metab J 1(4).PMID: 29292800 PMCID: PMC5747375","DOI":"10.31038\/EDMJ.2017141"},{"issue":"2","key":"2052_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020853","volume":"25","author":"S Pathak","year":"2024","unstructured":"Pathak S, Nadar R, Kim S et al (2024) The influence of kynurenine metabolites on neurodegenerative pathologies. Int J Mol Sci 25(2):853. https:\/\/doi.org\/10.3390\/ijms25020853","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2052_CR98","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/molecules13051035","volume":"13","author":"B Pavan","year":"2008","unstructured":"Pavan B, Dalpiaz A, Ciliberti N et al (2008) Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13(5):1035\u20131065. https:\/\/doi.org\/10.3390\/molecules13051035","journal-title":"Molecules"},{"key":"2052_CR99","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-1-4615-0135-0_71","volume":"527","author":"R Pellicciari","year":"2003","unstructured":"Pellicciari R, Amori L, Costantino G et al (2003) Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv Exp Med Biol 527:621\u2013628. https:\/\/doi.org\/10.1007\/978-1-4615-0135-0_71","journal-title":"Adv Exp Med Biol"},{"key":"2052_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108055","volume":"236","author":"AS Pires","year":"2022","unstructured":"Pires AS, Sundaram G, Heng B et al (2022) Recent advances in clinical trials targeting the kynurenine pathway. Pharmacol Ther 236:108055. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108055","journal-title":"Pharmacol Ther"},{"issue":"6","key":"2052_CR101","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1124\/pharmrev.124.000239","volume":"76","author":"A Pocivavsek","year":"2024","unstructured":"Pocivavsek A, Schwarcz R, Erhardt S (2024) Neuroactive kynurenines as pharmacological targets: new experimental tools and exciting therapeutic opportunities. Pharmacol Rev 76(6):978\u20131008. https:\/\/doi.org\/10.1124\/pharmrev.124.000239","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2052_CR102","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/anie.201408776","volume":"54","author":"S Pomplun","year":"2015","unstructured":"Pomplun S, Wang Y, Kirschner A et al (2015) Rational design and asymmetric synthesis of potent and neurotrophic ligands for FK506\u2010binding proteins (FKBPs). Angew Chem Int Ed Engl 54(1):345\u2013348. https:\/\/doi.org\/10.1002\/anie.201408776","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"2052_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115098","volume":"26","author":"D Pukoli","year":"2025","unstructured":"Pukoli D, V\u00e9csei L (2025) Kynurenines and mitochondrial disturbances in multiple sclerosis. Int J Mol Sci 26(11):5098. https:\/\/doi.org\/10.3390\/ijms26115098","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2052_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00680-x","volume":"18","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Dettmer U (2023) \u03b1-Synuclein serine129 phosphorylation\u2013the physiology of pathology. Mol Neurodegener 18(1):84. https:\/\/doi.org\/10.1186\/s13024-023-00680-x","journal-title":"Mol Neurodegener"},{"issue":"7","key":"2052_CR105","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2174\/1871527322666230609141519","volume":"23","author":"A Rasool","year":"2024","unstructured":"Rasool A, Manzoor R, Ullah K et al (2024) Oxidative stress and dopaminergic metabolism: A Major PD pathogenic mechanism and basis of potential antioxidant therapies. CNS Neurol Disord Drug Targets 23(7):852\u2013864. https:\/\/doi.org\/10.2174\/1871527322666230609141519","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"2052_CR106","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/wnl.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo G, Copetti M, Arcuti S et al (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86(6):566\u2013576. https:\/\/doi.org\/10.1212\/wnl.0000000000002350","journal-title":"Neurology"},{"key":"2052_CR107","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","volume":"109","author":"EM Rocha","year":"2018","unstructured":"Rocha EM, De Miranda B, Sanders LH (2018) Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease. Neurobiol Dis 109:249\u2013257. https:\/\/doi.org\/10.1016\/j.nbd.2017.04.004","journal-title":"Neurobiol Dis"},{"key":"2052_CR108","doi-asserted-by":"publisher","DOI":"10.1142\/S2737416525500991","author":"J Roshni","year":"2025","unstructured":"Roshni J, Mahema S, Janakiraman V et al (2025) Fragment screening and ligand breeding in designing novel defibrillators preventing Alpha synuclein tetramer aggregation in Parkinson\u2019s disease. J Comput Biophys Chem. https:\/\/doi.org\/10.1142\/S2737416525500991","journal-title":"J Comput Biophys Chem"},{"issue":"26","key":"2052_CR109","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1021\/jm970467t","volume":"40","author":"S R\u00f6ver","year":"1997","unstructured":"R\u00f6ver S, Cesura AM, Huguenin P et al (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40(26):4378\u20134385. https:\/\/doi.org\/10.1021\/jm970467t","journal-title":"J Med Chem"},{"issue":"1","key":"2052_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.598","volume":"7","author":"H Sakuta","year":"2017","unstructured":"Sakuta H, Suzuki K, Miyamoto T et al (2017) Serum uric acid levels in Parkinson\u2019s disease and related disorders. Brain Behav 7(1):e00598. https:\/\/doi.org\/10.1002\/brb3.598","journal-title":"Brain Behav"},{"issue":"3","key":"2052_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms4030035","volume":"4","author":"MJ Salas-Jara","year":"2016","unstructured":"Salas-Jara MJ, Ilabaca A, Vega M et al (2016) Biofilm forming Lactobacillus: new challenges for the development of probiotics. Microorganisms 4(3):35. https:\/\/doi.org\/10.3390\/microorganisms4030035","journal-title":"Microorganisms"},{"issue":"10","key":"2052_CR112","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","volume":"16","author":"ME Sanders","year":"2019","unstructured":"Sanders ME, Merenstein DJ, Reid G et al (2019) Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol 16(10):605\u2013616. https:\/\/doi.org\/10.1038\/s41575-019-0173-3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2052_CR113","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbi.2024.02.030","volume":"118","author":"HV Sandvig","year":"2024","unstructured":"Sandvig HV, Aam S, Alme KN et al (2024) Neopterin, kynurenine metabolites, and indexes related to vitamin B6 are associated with post-stroke cognitive impairment: the Nor-COAST study. Brain Behav Immun 118:167\u2013177. https:\/\/doi.org\/10.1016\/j.bbi.2024.02.030","journal-title":"Brain Behav Immun"},{"issue":"17","key":"2052_CR114","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1021\/acschemneuro.4c00355","volume":"15","author":"WT Santos","year":"2024","unstructured":"Santos WT, Katchborian-Neto A, Viana GS et al (2024) Metabolomics unveils disrupted pathways in Parkinson\u2019s disease: toward biomarker-based diagnosis. ACS Chem Neurosci 15(17):3168\u20133180. https:\/\/doi.org\/10.1021\/acschemneuro.4c00355","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"2052_CR115","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ et al (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13(7):465\u2013477. https:\/\/doi.org\/10.1038\/nrn3257","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2052_CR116","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/jad-181152","volume":"68","author":"Y Seino","year":"2019","unstructured":"Seino Y, Nakamura T, Kawarabayashi T et al (2019) Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases. J Alzheimers Dis 68(1):395\u2013404. https:\/\/doi.org\/10.3233\/jad-181152","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2052_CR117","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","volume":"55","author":"S-K Seo","year":"2023","unstructured":"Seo S-K, Kwon B (2023) Immune regulation through tryptophan metabolism. Exp Mol Med 55(7):1371\u20131379. https:\/\/doi.org\/10.1038\/s12276-023-01028-7","journal-title":"Exp Mol Med"},{"issue":"1","key":"2052_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00791-2","volume":"10","author":"N Shaheen","year":"2024","unstructured":"Shaheen N, Shaheen A, Osama M et al (2024) MicroRNAs regulation in Parkinson\u2019s disease, and their potential role as diagnostic and therapeutic targets. NPJ Parkinsons Dis 10(1):186. https:\/\/doi.org\/10.1038\/s41531-024-00791-2","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"2052_CR119","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10072-022-06490-1","volume":"44","author":"X Shi","year":"2023","unstructured":"Shi X, Zheng J, Ma J et al (2023) Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson\u2019s disease patients. Neurol Sci 44(3):881\u2013887. https:\/\/doi.org\/10.1007\/s10072-022-06490-1","journal-title":"Neurol Sci"},{"key":"2052_CR120","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neuro.2021.03.009","volume":"84","author":"RK Sodhi","year":"2021","unstructured":"Sodhi RK, Bansal Y, Singh R et al (2021) IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson\u2019s disease. Neurotoxicology 84:184\u2013197. https:\/\/doi.org\/10.1016\/j.neuro.2021.03.009","journal-title":"Neurotoxicology"},{"issue":"1","key":"2052_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"T-M Sonninen","year":"2020","unstructured":"Sonninen T-M, H\u00e4m\u00e4l\u00e4inen RH, Koskuvi M et al (2020) Metabolic alterations in Parkinson\u2019s disease astrocytes. Sci Rep 10(1):14474. https:\/\/doi.org\/10.1038\/s41598-020-71329-8","journal-title":"Sci Rep"},{"key":"2052_CR122","doi-asserted-by":"publisher","unstructured":"Sordillo PP and Sordillo LA (2022) Excess activity of 3-hydroxykynurenine, quinolinic acid, and other toxic tryptophan metabolites in neurogenerative diseases and other protein misfolding diseases. Biophotonics, Tryptophan and Disease. Elsevier, pp.115\u2013130. https:\/\/doi.org\/10.1016\/B978-0-12-822790-9.00005-X.","DOI":"10.1016\/B978-0-12-822790-9.00005-X"},{"issue":"5","key":"2052_CR123","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jnc.14843","volume":"151","author":"FJ Sorgdrager","year":"2019","unstructured":"Sorgdrager FJ, Vermeiren Y, Van Faassen M et al (2019) Age\u2010and disease\u2010specific changes of the kynurenine pathway in Parkinson\u2019s and Alzheimer\u2019s disease. J Neurochem 151(5):656\u2013668. https:\/\/doi.org\/10.1111\/jnc.14843","journal-title":"J Neurochem"},{"key":"2052_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00051","volume":"10","author":"D Stoessel","year":"2018","unstructured":"Stoessel D, Schulte C, dos Teixeira Santos MC et al (2018) Promising metabolite profiles in the plasma and CSF of early clinical Parkinson\u2019s disease. Front Aging Neurosci 10:51. https:\/\/doi.org\/10.3389\/fnagi.2018.00051","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2052_CR125","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jgh3.12450","volume":"5","author":"AH Tan","year":"2021","unstructured":"Tan AH, Hor JW, Chong CW et al (2021) Probiotics for Parkinson\u2019s disease: current evidence and future directions. JGH Open 5(4):414\u2013419. https:\/\/doi.org\/10.1002\/jgh3.12450","journal-title":"JGH Open"},{"issue":"9","key":"2052_CR126","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.3390\/ijms24098249","volume":"24","author":"EV Pershina","year":"2023","unstructured":"Pershina EV, Chernomorets IY, Fedorov DA, Arkhipov VI (2023) Pharmacological modulation of excitotoxicity through the combined use of NMDA receptor inhibition and group III mGlu activation reduces TMT-induced neurodegeneration in the rat hippocampus. Int J Mol Sci 24(9):8249. https:\/\/doi.org\/10.3390\/ijms24098249","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2052_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050607","volume":"18","author":"M Tanaka","year":"2025","unstructured":"Tanaka M, Szatm\u00e1ri I, V\u00e9csei L (2025) Quinoline quest: kynurenic acid strategies for next-generation therapeutics via rational drug design. Pharmaceuticals 18(5):607. https:\/\/doi.org\/10.3390\/ph18050607","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2052_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","volume":"208","author":"MG Tansey","year":"2007","unstructured":"Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson\u2019s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1\u201325. https:\/\/doi.org\/10.1016\/j.expneurol.2007.07.004","journal-title":"Exp Neurol"},{"issue":"1","key":"2052_CR129","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/rlu.0000000000001885","volume":"43","author":"S Tinaz","year":"2018","unstructured":"Tinaz S, Chow C, Kuo PH et al (2018) Semiquantitative analysis of dopamine transporter scans in patients with Parkinson disease. Clin Nucl Med 43(1):e1\u2013e7. https:\/\/doi.org\/10.1097\/rlu.0000000000001885","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2052_CR130","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW et al (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397. https:\/\/doi.org\/10.1016\/s1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"key":"2052_CR131","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/474135","volume":"2015","author":"N T\u00f6r\u00f6k","year":"2015","unstructured":"T\u00f6r\u00f6k N, T\u00f6r\u00f6k R, Szolnoki Z et al (2015) The genetic link between Parkinson\u2019s disease and the kynurenine pathway is still missing. Parkinsons Dis 2015:474135. https:\/\/doi.org\/10.1155\/2015\/474135","journal-title":"Parkinsons Dis"},{"issue":"11","key":"2052_CR132","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.dld.2017.07.011","volume":"49","author":"M Toscano","year":"2017","unstructured":"Toscano M, De Grandi R, Pastorelli L et al (2017) A consumer\u2019s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis 49(11):1177\u20131184. https:\/\/doi.org\/10.1016\/j.dld.2017.07.011","journal-title":"Dig Liver Dis"},{"issue":"12","key":"2052_CR133","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaneurol.2014.1909","volume":"71","author":"J Trinh","year":"2014","unstructured":"Trinh J, Guella I, Farrer MJ (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71(12):1535\u20131539. https:\/\/doi.org\/10.1001\/jamaneurol.2014.1909","journal-title":"JAMA Neurol"},{"issue":"3","key":"2052_CR134","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.neurobiolaging.2015.01.014","volume":"36","author":"A Van der Perren","year":"2015","unstructured":"Van der Perren A, Macchi F, Toelen J et al (2015) FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an \u03b1-synuclein-based rat model for Parkinson\u2019s disease. Neurobiol Aging 36(3):1559\u20131568. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.01.014","journal-title":"Neurobiol Aging"},{"key":"2052_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2020.100270","volume":"21","author":"D Venkatesan","year":"2020","unstructured":"Venkatesan D, Iyer M, Narayanasamy A et al (2020) Kynurenine pathway in Parkinson\u2019s disease\u2014an update. Eneurologicalsci 21:100270. https:\/\/doi.org\/10.1016\/j.ensci.2020.100270","journal-title":"Eneurologicalsci"},{"key":"2052_CR136","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.parkreldis.2019.02.014","volume":"63","author":"G Vivacqua","year":"2019","unstructured":"Vivacqua G, Suppa A, Mancinelli R et al (2019) Salivary alpha-synuclein in the diagnosis of Parkinson\u2019s disease and progressive supranuclear palsy. Parkinsonism Relat Disord 63:143\u2013148. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.014","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"2052_CR137","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3109\/00207454.2014.982795","volume":"125","author":"S Vivekanantham","year":"2015","unstructured":"Vivekanantham S, Shah S, Dewji R et al (2015) Neuroinflammation in Parkinson\u2019s disease: role in neurodegeneration and tissue repair. Int J Neurosci 125(10):717\u2013725. https:\/\/doi.org\/10.3109\/00207454.2014.982795","journal-title":"Int J Neurosci"},{"issue":"3-4","key":"2052_CR138","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.drudis.2012.09.001","volume":"18","author":"J Wang","year":"2013","unstructured":"Wang J, Hoekstra JG, Zuo C et al (2013) Biomarkers of Parkinson\u2019s disease: current status and future perspectives. Drug Discov Today 18(3\u20134):155\u2013162. https:\/\/doi.org\/10.1016\/j.drudis.2012.09.001","journal-title":"Drug Discov Today"},{"issue":"9","key":"2052_CR139","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1093\/brain\/awab156","volume":"144","author":"Q Wang","year":"2021","unstructured":"Wang Q, Luo Y, Ray Chaudhuri K et al (2021) The role of gut dysbiosis in Parkinson\u2019s disease: mechanistic insights and therapeutic options. Brain 144(9):2571\u20132593. https:\/\/doi.org\/10.1093\/brain\/awab156","journal-title":"Brain"},{"key":"2052_CR140","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neulet.2015.05.030","volume":"599","author":"X Wang","year":"2015","unstructured":"Wang X, Yu S, Li F et al (2015) Detection of \u03b1-synuclein oligomers in red blood cells as a potential biomarker of Parkinson\u2019s disease. Neurosci Lett 599:115\u2013119. https:\/\/doi.org\/10.1016\/j.neulet.2015.05.030","journal-title":"Neurosci Lett"},{"key":"2052_CR141","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.parkreldis.2022.08.020","volume":"103","author":"Y Wang","year":"2022","unstructured":"Wang Y, Bai L-P, Liu W et al (2022) Altered BDNF levels are associated with cognitive impairment in Parkinson\u2019s disease patients with depression. Parkinsonism Relat Disord 103:122\u2013128. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.020","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2052_CR142","doi-asserted-by":"publisher","first-page":"96","DOI":"10.21203\/rs.3.rs-4980210\/v1","volume":"11","author":"EN Wilson","year":"2025","unstructured":"Wilson EN, Umans J, Swarovski MS et al (2025) Parkinson\u2019s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. NPJ Parkinson\u2019s Dis 11(1):96. https:\/\/doi.org\/10.21203\/rs.3.rs-4980210\/v1","journal-title":"NPJ Parkinson\u2019s Dis"},{"issue":"1","key":"2052_CR143","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2017.06.007","volume":"22","author":"M Wlodarska","year":"2017","unstructured":"Wlodarska M, Luo C, Kolde R et al (2017) Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe 22(1):25\u201337. https:\/\/doi.org\/10.1016\/j.chom.2017.06.007","journal-title":"Cell Host Microbe"},{"issue":"8","key":"2052_CR144","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.cmet.2023.06.004","volume":"35","author":"C Xue","year":"2023","unstructured":"Xue C, Li G, Zheng Q et al (2023) Tryptophan metabolism in health and disease. Cell Metab 35(8):1304\u20131326. https:\/\/doi.org\/10.1016\/j.cmet.2023.06.004","journal-title":"Cell Metab"},{"key":"2052_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.07.003","volume":"581","author":"S Yadav","year":"2025","unstructured":"Yadav S, Raj RG (2025) Parkinson\u2019s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons. Neuroscience 581:1\u201315. https:\/\/doi.org\/10.1016\/j.neuroscience.2025.07.003","journal-title":"Neuroscience"},{"key":"2052_CR146","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neures.2017.06.008","volume":"128","author":"Y Yamagishi","year":"2018","unstructured":"Yamagishi Y, Saigoh K, Saito Y et al (2018) Diagnosis of Parkinson\u2019s disease and the level of oxidized DJ-1 protein. Neurosci Res 128:58\u201362. https:\/\/doi.org\/10.1016\/j.neures.2017.06.008","journal-title":"Neurosci Res"},{"key":"2052_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104589","volume":"91","author":"J Yan","year":"2023","unstructured":"Yan J, Kothur K, Mohammad S et al (2023) CSF neopterin, quinolinic acid and kynurenine\/tryptophan ratio are biomarkers of active neuroinflammation. EBioMedicine 91:104589. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104589","journal-title":"EBioMedicine"},{"issue":"1","key":"2052_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32480-0","volume":"13","author":"P Youssef","year":"2023","unstructured":"Youssef P, Hughes L, Kim WS et al (2023) Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting. Sci Rep 13(1):5217. https:\/\/doi.org\/10.1038\/s41598-023-32480-0","journal-title":"Sci Rep"},{"issue":"2","key":"2052_CR149","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-011-0697-3","volume":"119","author":"D Z\u00e1dori","year":"2012","unstructured":"Z\u00e1dori D, Kliv\u00e9nyi P, Toldi J et al (2012) Kynurenines in Parkinson\u2019s disease: therapeutic perspectives. J Neural Transm 119(2):275\u2013283. https:\/\/doi.org\/10.1007\/s00702-011-0697-3","journal-title":"J Neural Transm"},{"issue":"1","key":"2052_CR150","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-024-01459-4","volume":"44","author":"W Zeng","year":"2024","unstructured":"Zeng W, Cai J, Zhang L et al (2024) Iron deposition in Parkinson\u2019s disease: a mini-review. Cell Mol Neurobiol 44(1):26. https:\/\/doi.org\/10.1007\/s10571-024-01459-4","journal-title":"Cell Mol Neurobiol"},{"key":"2052_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2016.10.019","volume":"11","author":"C Zhang","year":"2017","unstructured":"Zhang C, Li C, Chen S et al (2017) Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K\/AKT\/Bcl-2 and Nrf2\/HO-1 pathways. Redox Biol 11:1\u201311. https:\/\/doi.org\/10.1016\/j.redox.2016.10.019","journal-title":"Redox Biol"},{"issue":"7","key":"2052_CR152","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-4583","volume":"9","author":"N Zhang","year":"2021","unstructured":"Zhang N, Tang C, Ma Q et al (2021a) Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson\u2019s disease. Ann Transl Med 9(7):559. https:\/\/doi.org\/10.21037\/atm-20-4583","journal-title":"Ann Transl Med"},{"key":"2052_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108702","volume":"697","author":"S Zhang","year":"2021","unstructured":"Zhang S, Collier MEW, Heyes DJ et al (2021b) Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Arch Biochem Biophys 697:108702. https:\/\/doi.org\/10.1016\/j.abb.2020.108702","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2052_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-019-0520-5","volume":"2","author":"S Zhang","year":"2019","unstructured":"Zhang S, Sakuma M, Deora GS et al (2019) A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun Biol 2(1):271. https:\/\/doi.org\/10.1038\/s42003-019-0520-5","journal-title":"Commun Biol"},{"issue":"1","key":"2052_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q et al (2023) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther 8(1):267. https:\/\/doi.org\/10.1038\/s41392-023-01486-5","journal-title":"Signal Transduct Target Ther"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02052-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:26:29Z","timestamp":1769703989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02052-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2052"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02052-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}